Cargando…
Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment
The myeloma bone marrow microenvironment promotes proliferation of malignant plasma cells and resistance to therapy. Activation of JAK/STAT signaling is thought to be a central component of these microenvironment-induced phenotypes. In a prior drug repurposing screen, we identified tofacitinib, a pa...
Autores principales: | Lam, Christine, Ferguson, Ian D., Mariano, Margarette C., Lin, Yu-Hsiu T., Murnane, Megan, Liu, Hui, Smith, Geoffrey A., Wong, Sandy W., Taunton, Jack, Liu, Jun O., Mitsiades, Constantine S., Hann, Byron C., Aftab, Blake T., Wiita, Arun P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ferrata Storti Foundation
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6029548/ https://www.ncbi.nlm.nih.gov/pubmed/29622655 http://dx.doi.org/10.3324/haematol.2017.174482 |
Ejemplares similares
-
DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma
por: Choudhry, Priya, et al.
Publicado: (2019) -
Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma
por: Huang, Hector H., et al.
Publicado: (2020) -
Evaluating the efficacy of multiple myeloma cell lines as models for patient tumors via transcriptomic correlation analysis
por: Sarin, Vishesh, et al.
Publicado: (2020) -
Unraveling the surface proteomic profile of multiple myeloma to reveal new immunotherapeutic targets and markers of drug resistance
por: Patiño-Escobar, Bonell, et al.
Publicado: (2022) -
Stimulatory Effect of Tofacitinib on Bone Marrow Adipocytes Differentiation
por: Letarouilly, Jean-Guillaume, et al.
Publicado: (2022)